Behavioral and Neuroendocrine Effects of a Selective Kappa Opioid Receptor Antagonist
Purpose
This study will determine the impact of selective kappa-opioid receptor (KOPr) antagonism with the novel Lilly compound OpRA Kappa (LY2456302) in persons at specific stages in cocaine addiction trajectory compared to normal healthy volunteers. KOPr receptors (encoded by gene OPRK1) and their endogenous neuropeptide ligands (the dynorphins encoded by gene PDYN) they are upregulated in addictive diseases and in other neuropsychiatric diseases. This upregulation may be due to chronic exposure to drugs of abuse such as cocaine due to stress exposure or as part of the etiology of the disease. Increased signaling through KOPr is thought to result in a relapse-prone state and to cause dysphoria / anhedonia in humans. KOPr antagonists thus represent a novel potential therapeutic strategy in cocaine addiction and related depressive symptoms a disease associated with massive public health morbidity and for which no pharmacotherapies exist
Condition
- Addictive diseases
Eligibility
- Eligible Ages
- Between 18 and 65
- Eligible Genders
- 1
- Accepts Healthy Volunteers
- Yes
Study Design
- Phase
- early Phase 1
- Study Type
- Observational
More Details
- Status
- Recruiting
- Sponsor
- Rockefeller University